Ultragenyx Pharmaceutical (NASDAQ:RARE) PT Lowered to $60.00
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) had its price target reduced by Evercore ISI to $60.00 in a report issued on Tuesday, Stock Target Advisor reports. Evercore ISI's target price would indicate a potential upside of 15.03% from the stock's current price.
Several other brokerages have also recently commented on RARE. The Goldman Sachs Group decreased their target price on Ultragenyx Pharmaceutical from $139.00 to $101.00 and set a 'neutral' rating on the stock in a report on Tuesday, May 24th.
Article
Ready for ...
Envista (N...
Harry coul...
Ultragenyx...
Perkins Ca...
M&T Bank C...
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Praesent placerat ipsum nec mi maximus, vel cursus mauris cursus. Vivamus cursus ante eget orci egestas malesuada.
Article
ETHA Lend ...
Deutsche W...
Ready for ...
Envista (N...
Harry coul...
Ultragenyx...